BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 2019;38:2977-94. [PMID: 31367943 DOI: 10.1007/s10067-019-04699-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin Arthritis Rheum 2020;50:930-7. [PMID: 32906027 DOI: 10.1016/j.semarthrit.2020.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Moon H, Ko M, Park Y, Kim J, Yoon D, Lee E, Lee T, Kim H. Δ8(14)-Ergostenol Glycoside Derivatives Inhibit the Expression of Inflammatory Mediators and Matrix Metalloproteinase. Molecules 2021;26:4547. [PMID: 34361701 DOI: 10.3390/molecules26154547] [Reference Citation Analysis]
3 Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther 2021;34:e14633. [PMID: 33280226 DOI: 10.1111/dth.14633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang X, Du W, Zhang X, Li P. The Influence of Different Disease States on Rituximab Pharmacokinetics. Curr Drug Metab 2020;21:938-46. [PMID: 32682367 DOI: 10.2174/1389200221666200719004035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bonasia CG, Abdulahad WH, Rutgers A, Heeringa P, Bos NA. B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells. Cells 2021;10:1190. [PMID: 34068035 DOI: 10.3390/cells10051190] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Blüml S. [Biologicals and small molecules for rheumatoid arthritis]. Z Rheumatol 2020;79:223-31. [PMID: 32179964 DOI: 10.1007/s00393-020-00766-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Yoo DH, Suh CH, Shim SC, Lee SJ, Kim SH, Park W. A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2020;16:1125-32. [PMID: 33012214 DOI: 10.1080/17425255.2020.1832082] [Reference Citation Analysis]
8 Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int 2021;21:614. [PMID: 34809619 DOI: 10.1186/s12935-021-02325-9] [Reference Citation Analysis]
9 Kim J, Islam SMT, Qiao F, Singh AK, Khan M, Won J, Singh I. Regulation of B cell functions by S-nitrosoglutathione in the EAE model. Redox Biol 2021;45:102053. [PMID: 34175668 DOI: 10.1016/j.redox.2021.102053] [Reference Citation Analysis]
10 Kim DW, Cho JY. Recent Advances in Allogeneic CAR-T Cells. Biomolecules 2020;10:E263. [PMID: 32050611 DOI: 10.3390/biom10020263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
11 Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci 2020;27:76. [PMID: 32586313 DOI: 10.1186/s12929-020-00652-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval? Front Immunol 2021;12:661882. [PMID: 34295328 DOI: 10.3389/fimmu.2021.661882] [Reference Citation Analysis]
13 Miller AJ, Doherty TA. Hop to It: The First Animal Model of Autoimmune Postural Orthostatic Tachycardia Syndrome. J Am Heart Assoc 2019;8:e014084. [PMID: 31547756 DOI: 10.1161/JAHA.119.014084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Nooreen R, Nene S, Jain H, Prasannanjaneyulu V, Chitlangya P, Otavi S, Khatri DK, Raghuvanshi RS, Singh SB, Srivastava S. Polymer nanotherapeutics: A versatile platform for effective rheumatoid arthritis therapy. J Control Release 2022;348:397-419. [PMID: 35660632 DOI: 10.1016/j.jconrel.2022.05.054] [Reference Citation Analysis]
15 El-kady RAE, Fathy A, Othman T, Hafez E. Could potentially calprotectin be a promising biomarker to oracle biologic therapy response in rheumatoid arthritis? Egypt Rheumatol Rehabil 2021;48. [DOI: 10.1186/s43166-021-00094-x] [Reference Citation Analysis]
16 Kim JW, Jung JY, Shin K, Suh CH, Kim HA. Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis. Front Med (Lausanne) 2021;8:765535. [PMID: 34778324 DOI: 10.3389/fmed.2021.765535] [Reference Citation Analysis]
17 Zhang Y, Gao Z, Chao S, Lu W, Zhang P. Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis. Drug Deliv 2022;29:1934-50. [PMID: 35757855 DOI: 10.1080/10717544.2022.2089295] [Reference Citation Analysis]
18 Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, Strangfeld A, Gossec L, Carmona L, Mateus EF, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Pons-Estel GJ, Isnardi CA, Berbotto GA, Hsu TY, D'Silva KM, Patel NJ, Kearsley-Fleet L, Schäfer M, Ribeiro SLE, Al Emadi S, Tidblad L, Scirè CA, Raffeiner B, Thomas T, Flipo RM, Avouac J, Seror R, Bernardes M, Cunha MM, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, Souza VA, Mota LMHD, Gomides APM, Dieudé P, Nikiphorou E, Kronzer VL, Singh N, Ugarte-Gil MF, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Yazdany J; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021;80:1137-46. [PMID: 34049860 DOI: 10.1136/annrheumdis-2021-220418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
19 Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Interleukin-6 in Rheumatoid Arthritis. Int J Mol Sci 2020;21:E5238. [PMID: 32718086 DOI: 10.3390/ijms21155238] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
20 Bugaj B, Wielińska J, Bogunia-kubik K, Świerkot J. Searching for New Genetic Biomarkers of Axial Spondyloarthritis. JCM 2022;11:2912. [DOI: 10.3390/jcm11102912] [Reference Citation Analysis]
21 Cruz RA, Chaudhary S, Guevara M, Meltzer E. Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist. Curr Rheumatol Rep 2021;23:33. [PMID: 33909180 DOI: 10.1007/s11926-021-01000-2] [Reference Citation Analysis]
22 Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells 2020;9:E880. [PMID: 32260219 DOI: 10.3390/cells9040880] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 16.0] [Reference Citation Analysis]
23 Ponticelli C, Doria A, Moroni G. Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). J Nephrol 2021;34:1081-90. [PMID: 32548773 DOI: 10.1007/s40620-020-00776-3] [Reference Citation Analysis]
24 Neurath MF. Resolution of inflammation: from basic concepts to clinical application. Semin Immunopathol 2019;41:627-31. [DOI: 10.1007/s00281-019-00771-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Saalfeld W, Mixon AM, Zelie J, Lydon EJ. Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. Rheumatol Ther 2021;8:1493-517. [PMID: 34519965 DOI: 10.1007/s40744-021-00365-1] [Reference Citation Analysis]
26 Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]
27 Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. J Eur Acad Dermatol Venereol 2021;35:797-806. [PMID: 33533553 DOI: 10.1111/jdv.17075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Hanaoka R, Haginoya T, Koike M. A case of rheumatoid arthritis complicated with mucous membrane pemphigoid. Mod Rheumatol Case Rep 2021;5:191-4. [PMID: 33081597 DOI: 10.1080/24725625.2020.1839196] [Reference Citation Analysis]
29 Cotchett KR, Dittel BN, Obeidat AZ. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. Mult Scler Relat Disord 2021;49:102787. [PMID: 33516134 DOI: 10.1016/j.msard.2021.102787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]